Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266147 · ClinicalTrials.gov registry record · Phase 1
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02266147 is a Phase 1 study that was terminated before completion, run by Dynavax Technologies Corporation. The registered enrollment target is 29 participants.
The verdict
NCT02266147, a Phase 1 study, was terminated before completion, sponsored by Dynavax Technologies Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
Interventions
- RADIATION Radiation therapy
- DRUG SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266147
The ClinicalTrials.gov registry entry for NCT02266147 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation therapy is the first listed.
NCT02266147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266147 about?
NCT02266147 is a clinical study titled "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma". To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
What is the current status of trial NCT02266147?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-10. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02266147?
The interventions under investigation include: Radiation therapy (RADIATION), SD-101 (DRUG).
Who is sponsoring clinical trial NCT02266147?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.